Table 1.
Clinical and pathological characteristics of all oncocytic thyroid tumors
| Case ID | Diagnosis | Age at Diagnosis (years) | Sex | Tumor size (cm) | Capsular invasion | Vascular invasion | WHO 2022 tumor subtype | TNM |
|---|---|---|---|---|---|---|---|---|
| 1 | OCA | 62 | F | 2 | N | Y | EA | pT2NxMx |
| 2 | OCA | 51 | M | 2.2 | Y | Y | EA | pT2NxMx |
| 3 | OCA | 55 | F | 0.3 | N | Y | EA | pT1aNxMx |
| 4* | OCA | 75 | F | 2.6 | Y | Y | WI | pT2NxMx |
| 5* | OCA | 58 | F | 1.4 | Y | N | MI | pT1bNxMx |
| 6 | OCA | 47 | F | 1.8 | N | Y | EA | pT1bNxMx |
| 7* | OCA | 48 | F | 1.8 | N | Y | EA | pT1bNxMx |
| 8 | OCA | 86 | F | 5.5 | N | Y | EA | pT3NxMx |
| 9* | OCA | 59 | F | 2 | Y | Y | EA | pT2NxMx |
| 10* | OCA | 28 | F | 4 | N | Y | EA | pT2NxMx |
| 11* | OCA | 31 | F | 2.5 | N | Y | EA | pT2NxMx |
| 12* | OCA | 71 | F | 1.2 | Y | N | MI | pT1bNxMx |
| 13 | OCA | 58 | F | 4 | Y | N | MI | pT3NxMx |
| 14 | OCA | 53 | M | 4 | Y | Y | EA | pT3NxMx |
| 15 | OCA | 44 | M | 4.5 | N | Y | EA | pT3NxMx |
| 16 | OCA | 40 | F | 2 | Y | Y | WI | pT2NxMx |
| 17 | OCA | 37 | F | 3 | Y | Y | EA | pT2NxMx |
| 18 | OCA | 53 | F | 2.5 | Y | N | MI | pT2NxMx |
| 19 | OCA | 65 | F | 4.5 | Y | Y | EA | pT3NxMx |
| 20 | OCA | 82 | F | 10 | Y | Y | EA | pT4aNxMx |
| 21 | OCA | 64 | F | 2.1 | Y | Y | WI | pT2NxMx |
| 22 | OCA | 51 | M | 2.1 | N | Y | EA | pT2NxMx |
| 23 | OCA | 40 | F | 0.5 | Y | Y | WI | pT1aNxMx |
| 24 | OCA | 72 | M | 3.2 | N | Y | EA | pT3NxMx |
| 25 | OCA | 54 | F | 3 | Y | Y | EA | pT2NxMx |
| 26 | OCA | 68 | F | 10 | Y | Y | EA | pT3N0Mx |
| 27 | OCA | 59 | F | 0.5 | Y | Y | EA | pT1aNxMx |
| 28* | OA | 67 | F | 3 | N | N | NA | NA |
| 29 | OA | 51 | M | 2.2 | N | N | NA | NA |
| 30 | OA | 48 | F | 1 | N | N | NA | NA |
| 31 | OA | 63 | F | 1.8 | N | N | NA | NA |
| 32 | OA | 42 | F | 4 | N | N | NA | NA |
| 33 | OA | 39 | F | 1 | N | N | NA | NA |
| 34 | OA | 44 | F | 4 | N | N | NA | NA |
| 35 | OA | NR | F | 3.5 | N | N | NA | NA |
| 36 | OA | 27 | F | 2 | N | N | NA | NA |
| 37 | OA | NR | F | 4 | N | N | NA | NA |
| 38 | OA | 53 | M | 2 | N | N | NA | NA |
| 39 | OA | 41 | F | 2.5 | N | N | NA | NA |
| 40* | OA | 50 | F | 4 | N | N | NA | NA |
| 41 | OA | 68 | F | NR | N | N | NA | NA |
| 42 | OA | NR | F | 3.5 | N | N | NA | NA |
| 43 | OA | 79 | F | 12 | N | N | NA | NA |
| 44 | OA | 62 | F | 2.2 | N | N | NA | NA |
| 45 | OA | 43 | F | 2 | N | N | NA | NA |
| 46 | OA | 66 | F | 3.5 | N | N | NA | NA |
| 47 | OA | 73 | F | 4.5 | N | N | NA | NA |
| 48 | OA | 35 | F | 2.5 | N | N | NA | NA |
| 49 | OA | 53 | F | 6.5 | N | N | NA | NA |
| 50 | OA | 64 | F | 0.8 | N | N | NA | NA |
| 51 | OA | 29 | F | 1.8 | N | N | NA | NA |
| 52 | OA | 64 | M | 1.8 | N | N | NA | NA |
| 53 | OA | 23 | F | 5.5 | N | N | NA | NA |
| 54 | OA | 66 | F | 2.1 | N | N | NA | NA |
| 55 | OA | 51 | F | 0.7 | N | N | NA | NA |
| 56 | OA | 27 | F | 2.5 | N | N | NA | NA |
*STRN::ALK fusion positive cases; OCA Oncocytic Carcinoma of the Thyroid, OA Oncocytic Adenoma of the Thyroid, F Female, M Male, NR Not Reported, Y Yes, N No, MI Minimally invasive, WI Widely invasive, EA Encapsulated angioinvasive, NA Not Applicable, pTNM staging was applied only to malignant tumors according to AJCC criteria